December 1, 2018 Brief Overview: Assessment of Compound-induced Acute Kidney Injury Using Animal Models, Biomarkers, and In Vitro Platforms
November 28, 2018 Sharing Data to Accelerate Medicines Development and Improve Neonatal Care: Data Standards and Harmonized Definitions
November 8, 2018 Profiles in Business with Tucson Metro Chamber C-Path President and CEO Martha Brumfield, Ph.D., talks about today’s drug discovery process, C-Path’s global impact a
November 5, 2018 Critical Path Institute Rebrands One of Its First Consortia to Highlight Focus on Alzheimer’s Disease Critical Path for Alzheimer’s Disease (CPAD) consortium’s refined, refocused mission centers on accelerating therapy developme
November 3, 2018 D-RSC and PSTC presented “Biomarkers for Muscle Diseases” poster at the 2018 MDA Clinical Conference
November 3, 2018 D-RSC presents poster on advancing drug development for Duchenne through data sharing and quantitative tool development at the 2018 MDA Clinical Conference
November 1, 2018 Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective
November 1, 2018 C-Path, CHDI and CDISC Announce Therapeutic Area User Guide for Huntington’s Disease TUCSON, Ariz., NEW YORK and AUSTIN, Texas, November 1, 2018 — The Huntington’s Disease Regulatory Science Consortium (HD-RSC),
October 25, 2018 FNIH Biomarkers Consortium and Critical Path Institute Achieve the First Ever Qualification of a Clinical Safety Biomarker by the U.S. Food and Drug Administration Major Milestone will Improve Detection of Drug-Induced Acute Kidney Injury in Clinical Trials. October 25, 2018 —
October 11, 2018 Comparability of a Provisioned Device Versus Bring Your Own Device for Completion of Patient-Reported Outcome (PRO) Measures by Participants with Chronic Obstructive Pulmonary Disease (COPD): Quantitative Interview Findings
